1. Pink Sheet
  2. >>Geography

European Opportunities Loom For Value Added Medicines

But Sales Still Lag US, With EU Legislative Review Set To Address Sector’s Need For Reform

 
• By Dave Wallace

Upcoming opportunities facilitated by the EU’s pharma legislation review were highlighted at Medicines for Europe’s fifth annual value added medicines conference, held in Brussels this month. However, enthusiasm was tempered with acknowledgements that the European sector current lags behind the US and needs further reform to attract investment.

Medicines for Europe 5th Value Added Medicines conference panel
Panelists discussed opportunities and obstacles for value added medicines at Medicines for Europe’s fifth annual conference • Source: Medicines for Europe

A mood of cautious optimism was apparent at Medicines for Europe’s fifth annual value added medicines conference, held in Brussels in early November, with delegates hearing suggestions from a number of speakers that the EU’s current review of pharma legislation promised to open up new opportunities for the sector.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography